Published in Virchows Arch on November 23, 2006
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res (2008) 2.69
Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer (2010) 1.58
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res (2009) 1.28
Demystifying basal-like breast carcinomas. J Clin Pathol (2007) 1.22
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer (2010) 1.19
P-cadherin expression in breast cancer: a review. Breast Cancer Res (2007) 1.09
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer (2011) 0.96
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. J Mol Histol (2013) 0.87
Biomarkers for Basal-like Breast Cancer. Cancers (Basel) (2010) 0.86
Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. J Histochem Cytochem (2015) 0.81
Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. Clinics (Sao Paulo) (2013) 0.80
The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer (2014) 0.80
P-cadherin and the journey to cancer metastasis. Mol Cancer (2015) 0.80
Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer? Int J Surg Oncol (2012) 0.80
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene (2015) 0.79
CCAAT/enhancer binding protein β (C/EBPβ) isoforms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in human breast cancer cells. PLoS One (2013) 0.77
Molecular characterisation of breast cancer patients at high and low recurrence risk. Virchows Arch (2008) 0.76
Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomas. BMC Vet Res (2014) 0.75
Ductal carcinoma in situ of the breast: correlation between histopathological features and age of patients. Diagn Pathol (2014) 0.75
P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. Mod Pathol (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res (1999) 2.02
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol (1999) 1.76
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch (2005) 1.69
Epidemiology of breast cancer in young women. Breast Dis (2006) 1.63
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res (2005) 1.51
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol (2005) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol (1990) 1.26
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol (2006) 1.22
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle (2006) 1.17
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol (2005) 1.14
Molecular classification of breast cancer patients by gene expression profiling. J Pathol (2001) 1.08
The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract (2005) 1.01
P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch (2002) 0.91
Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci (2006) 0.81
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 2.33
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr (2012) 1.70
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer (2010) 1.58
CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol (2012) 1.51
Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res (2005) 1.47
P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res (2005) 1.36
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res (2011) 1.30
Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol (2006) 1.28
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res (2009) 1.28
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res (2011) 1.27
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch (2003) 1.24
p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol (2002) 1.22
Comparison of manual and automated methods of liquid-based cytology. A morphologic study. Acta Cytol (2004) 1.16
Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol (2003) 1.15
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol (2011) 1.14
Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer (2011) 1.14
Desmoplastic small round cell tumour: Cytological and immunocytochemical features. Cytojournal (2005) 1.12
P-cadherin expression in breast cancer: a review. Breast Cancer Res (2007) 1.09
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn (2008) 1.09
The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90β. Genes Dev (2013) 1.08
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol (2009) 1.08
Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer (2008) 1.07
Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix. Gynecol Oncol (2007) 1.06
Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol (2006) 1.05
P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res (2004) 1.05
Pediatric pigmented dermatofibrosarcoma protuberans (Bednár tumor): case report and review of the literature with emphasis on the differential diagnosis. Pathol Res Pract (2002) 1.02
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
17 beta -estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis (2003) 1.00
Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol (2002) 0.99
Intradermal spindle cell/pleomorphic lipoma of the vulva: case report and review of the literature. J Cutan Pathol (2002) 0.98
Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res (2008) 0.98
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer (2009) 0.98
Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch (2002) 0.97
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer (2011) 0.96
Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer (2003) 0.95
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol (2006) 0.95
P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol (2010) 0.95
MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer (2010) 0.94
Pathologic quiz case: a 62-year-old woman with a 4.5-cm nodule in the right breast. Lipid-rich breast carcinoma. Arch Pathol Lab Med (2003) 0.92
Vascular endothelial growth factor, transforming growth factor-alpha, and estrogen receptors: possible cross-talks and interactions. Am J Pathol (2002) 0.92
Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr (2006) 0.92
How useful is the assessment of lymphatic vascular density in oral carcinoma prognosis? World J Surg Oncol (2007) 0.91
P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch (2002) 0.91
Angiogenesis and breast cancer. J Oncol (2010) 0.90
Lymphangiogenesis in tumors: what do we know? Microsc Res Tech (2003) 0.90
VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract (2005) 0.89
Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol (2005) 0.88
Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study. Diagn Cytopathol (2002) 0.88
Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol (2007) 0.87
Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol (2014) 0.86
Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Dev Cell (2009) 0.86
Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr Relat Cancer (2013) 0.86
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet (2009) 0.86
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology (2012) 0.85
Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med (2014) 0.85
Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract (2002) 0.85
ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. Hum Mol Genet (2010) 0.84
Hyaline cell-rich chondroid syringoma: case report and review of the literature. Pathol Res Pract (2002) 0.83
Fine-needle aspiration cytology of pulmonary rheumatoid nodule: case report and review of the major cytologic features. Diagn Cytopathol (2002) 0.83
Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology (2009) 0.83
KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecol Oncol (2008) 0.83
Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol (2003) 0.82
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol (2007) 0.82
Maspin is expressed in the nuclei of breast myoepithelial cells. J Pathol (2002) 0.81
A new model of laryngitis: neuropeptide, cyclooxygenase, and cytokine profile. Laryngoscope (2008) 0.80
Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma. Diagn Cytopathol (2007) 0.80
Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol (2011) 0.80
Liquid-based cytology in fine-needle aspiration of breast lesions: a review. Acta Cytol (2014) 0.80
Epithelioid malignant peripheral nerve sheath tumour: case report and review of the previously published cases. Cytopathology (2002) 0.80
The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer (2014) 0.80
Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance. Oncol Lett (2012) 0.79
P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol Res Pract (2003) 0.79
Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? Breast (2002) 0.79
Liquid-based cytology in DNA-based molecular research: viability and potential application. Anal Quant Cytol Histol (2009) 0.79
Clinicopathologic features of mammary invasive micropapillary carcinoma (IMC) in dogs. Vet Pathol (2008) 0.79
[Basal-like carcinoma of the breast]. Acta Med Port (2008) 0.78
Naked nuclei revisited: p63 Immunoexpression. Diagn Cytopathol (2002) 0.78
P-cadherin expression in canine lactating mammary gland. J Cell Biochem (2002) 0.78